Kaufman Hall acquires Healthcare Real Estate Capital

Healthcare consulting and advisory services firm Kaufman, Hall & Associates has acquired Healthcare Real Estate Capital, a national advisory firm focused on the healthcare and higher education real estate capital markets sectors.

Kaufman Hall is known for its M&A services and its significant capital markets business. The firm also regularly publishes healthcare M&A industry reports and data. HR Capita provides strategic consulting and transaction advisory services to some of the nation's largest healthcare institutions, including for-profit and non-profit hospitals/health systems, universities/academic institutions, physician practices, developers, and institutional investors such as real estate investment trusts (REITs) and private equity firms. 

Both firms cover niche real estate capital markets for healthcare and higher education.

The acquisition comes at a time when the healthcare sector is experiencing a historic transformation in how services are delivered. The COVID-19 pandemic has forced healthcare providers to do more in unprecedented times, while investor demand and capital flowers for the sector accelerates. 

“Real estate is a very significant and valuable asset for healthcare and higher education institutions, and our clients need independent, strategic advice to guide their operational and financial decision making,” R. Wesley Champion, managing director and chief executive officer of Kaufman Hall said in a press release. “HRE Capital has unmatched experience in the niche real estate capital markets for both sectors and has close relationships with highly regarded institutional investors and developer/operators. Together, Kaufman Hall and HRE Capital will deliver the rigorous analytics, unwavering advocacy, and service excellence our clients rely on to a broader range of institutions and will help C-Suite leaders in healthcare and higher education unlock value in this critical financial asset.”

Financial terms of the deal were not disclosed.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.